{"id":34577,"date":"2021-10-28T04:20:56","date_gmt":"2021-10-28T04:20:56","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=81435"},"modified":"2021-10-28T04:20:56","modified_gmt":"2021-10-28T04:20:56","slug":"launch-of-seegenes-starlet-aios-all-in-one-system-fulfills-critical-need-for-fully-automated-high-throughput-real-time-pcr-testing","status":"publish","type":"post","link":"https:\/\/southafricagazette.com\/launch-of-seegenes-starlet-aios-all-in-one-system-fulfills-critical-need-for-fully-automated-high-throughput-real-time-pcr-testing\/","title":{"rendered":"Launch of Seegene\u2019s STARlet-AIOS: All-in-One System Fulfills Critical Need for Fully Automated, High-Throughput Real-Time PCR Testing"},"content":{"rendered":"
SEOUL, South Korea, Oct. 28, 2021 \/PRNewswire\/ — South Korea’s leading molecular diagnostics (MDx) developer Seegene Inc., (KQ 096530) is addressing the needs of small, mid-sized, and large hospitals and COVID-19 laboratories with its fully automated STARlet-AIOS: All-in-One System (AIOS). First unveiled at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo in Atlanta, the modular system supports a “hands-free” PCR workflow, automating everything from nucleic acid extraction to the interpretation of results.\u00a0This can help sites boost their testing capacity while lessening the burden on laboratory and hospital staff.<\/p>\n
“Seegene has played a critical role in the global response to the COVID-19 pandemic, in large part because of our forward-looking strategy. We moved fast from day one, rapidly developing a reliable assay for the novel coronavirus and then pivoting to multiplexed tests that can detect emerging SARS-CoV-2\u00a0variants,” said Dr. Jong-Yoon Chun, Seegene Founder and CEO. “As we look ahead, the most pressing diagnostic need will be for cost-effective and high throughput automated systems that can remove any remaining testing bottlenecks. Our all-in-one system specifically addresses that need for hospitals and laboratories of all sizes.”<\/p>\n
More than 3.75 billion people worldwide have now received at least one dose of a COVID-19 vaccine. As daily case counts and fatalities decline, many countries are easing their restrictions and preparing to live with the virus. Doing so safely will require ongoing surveillance, with accurate PCR testing and rapid turnaround times.<\/p>\n
The modular design of\u00a0STARlet-AIOS: All-in-One System\u00a0unites two\u00a0standalone instruments\u2013\u2013the STARlet IVD and the CFX96\u2122 Dx real-time PCR System\u2013\u2013with\u00a0a custom-built robotic arm. This unique engineering allows customers to\u00a0either purchase the full\u00a0AIOS system or integrate existing Seegene instruments already in use.\u00a0With its\u00a0compact\u00a0and\u00a0intuitive design,\u00a0the AIOS is\u00a0accessible\u00a0to small-to-medium sized hospitals and clinics, along with larger organizations.<\/p>\n
Seegene’s current portfolio with an extensive test menu including GI, HPV, STI, respiratory assays as well as a suite of SARS-CoV-2\u00a0assays detecting a wide range of variants (namely, Alpha, Beta, Gamma, Delta, Epsilon, kappa, Lambda, Mu, etc.) can all be processed using the AIOS. The system will also be compatible with newly developed assays and Seegene’s\u00a0MOBILE STATION<\/a><\/u>, an innovative laboratory-on-wheels initiative that delivers mass testing capacity to communities that would otherwise lack the necessary infrastructure.<\/p>\n Meanwhile, the company plans to introduce Allplex\u2122\u00a0Respiratory Virus Master Assay, in late 2021, a single tube syndromic assay that can\u00a0differentiate between COVID-19 and other major common respiratory pathogens, such as influenza, RSV, adenovirus, parainfluenza, metapneumovirus, human rhinovirus.\u00a0The introduction of the new assay will help doctors treat cases more effectively, by differentiating causative pathogens of COVID-19 and respiratory viruses for common flu, which may surge in winter season.<\/p>\n